HK Stock Market Move | JUNSHI BIO (01877) rose more than 6%. Tropic-2 antibody has been approved by the European Commission for listing.

JUNSHI BIO (01877) rose more than 6%, rising 6.46% to HK$11.86 as of the time of writing, with a turnover of HK$98.49 million. On the news front, JUNSHI BIO announced that its self-developed anti-PD-1 monoclonal antibody drug Toripalimab (European brand name: LOQTORZI) recently received approval from the European Commission (EC) for two indications: Toripalimab in combination with cisplatin and gemcitabine for first-line treatment of recurrent, unresectable or radiotherapy-refractory, or metastatic nasopharyngeal carcinoma (NPC) in adults; and Toripalimab in combination with cisplatin and paclitaxel for first-line treatment of unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in adults. JUNSHI BIO stated that this approval signifies Toripalimab becoming the first and only drug for the treatment of nasopharyngeal carcinoma in Europe, as well as the only first-line treatment drug for unresectable advanced or metastatic esophageal squamous cell carcinoma in Europe without restrictions on PD-L1 expression. This approval is favorable for the company to further expand into overseas markets, enhance the international influence of its products, and is expected to have a positive impact on the company's long-term operating performance.